Core Viewpoint - InnoCare Pharma has presented over 20 studies on its BTK inhibitor orelabrutinib at the 67th Annual Meeting of the American Society of Hematology, highlighting its efficacy and safety in treating various lymphomas and chronic lymphocytic leukemia [1][2]. Group 1: Efficacy and Safety of Orelabrutinib - Orelabrutinib has shown significant efficacy in multiple lymphoma types, including marginal zone lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia, primary central nervous system lymphoma, and diffuse large B-cell lymphoma [2]. - In a study involving newly diagnosed primary central nervous system lymphoma, the combination of orelabrutinib, rituximab, and high-dose methotrexate achieved an objective response rate (ORR) of 89.5% and a complete response (CR) rate of 78.9% [4]. - The orelabrutinib and obinutuzumab combination demonstrated an ORR of 96.0% in treatment-naïve marginal zone lymphoma patients, with no severe toxicities reported [5][6]. Group 2: Treatment Outcomes and Comparisons - The orelabrutinib plus bendamustine-rituximab regimen showed promising tumor response and survival outcomes compared to the standard bendamustine-rituximab regimen in transplant-ineligible, intermediate- to high-risk mantle cell lymphoma [9]. - In a large-scale real-world study of diffuse large B-cell lymphoma in China, the R-CHOP regimen combined with orelabrutinib achieved a CR rate of 81.4% in MCD-like patients, supporting subtype-directed therapy [11]. - A prospective phase II study indicated that the combination of pomalidomide, rituximab, and orelabrutinib is a potential treatment option for elderly, unfit, or frail patients with diffuse large B-cell lymphoma, achieving a CR rate of 77.8% among those who completed three cycles [12][13][14]. Group 3: Future Research and Development - Additional studies on orelabrutinib have been selected for poster presentation and publication at the 2025 ASH Annual Meeting, indicating ongoing research and development efforts [15]. - InnoCare is committed to discovering and commercializing innovative drugs for cancer and autoimmune diseases, with a focus on addressing unmet medical needs [17].